Artigo Acesso aberto Revisado por pares

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

2013; Elsevier BV; Volume: 122; Issue: 10 Linguagem: Inglês

10.1182/blood-2013-06-506725

ISSN

1528-0020

Autores

Roland B. Walter, Sarah Buckley, John M. Pagel, Brent L. Wood, Barry E. Storer, Brenda M. Sandmaier, Min Fang, Boglarka Gyurkocza, Colleen Delaney, Jerald P. Radich, Elihu H. Estey, Frederick R. Appelbaum,

Tópico(s)

Retinoids in leukemia and cellular processes

Resumo

Key Points The negative impact of pre-HCT flow cytometrically determined MRD is similar for AML in CR1 and CR2. Even minute levels of MRD (≤0.1%) are associated with adverse outcome.

Referência(s)